Several seminal studies demonstrated CD133+ glioma cells exhibited enhanced ability to evade treatment and increased EMT incidence leading to distant metastasis, both contributing to the high mortality of patients with high grade glioblastoma [11, 14]. This evidence concerns the gene PROM1 and central nervous system cancer.